Mesoblast gets EMA nod to start Revascor Phase 2 trial
The Phase 2 trial – Allogeneic Mesenchymal precursor cell Infusion in myoCardial Infarction (AMICI) – is expected to initially enroll patients at multiple European sites, including in the
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
Premier Source provides consulting and reimbursement services to medical device, pharmaceutical, molecular diagnostic and biotechnology manufacturers, as well as other health services companies. AmerisourceBergen Business Development senior vice